All In Biotech

NDA 021457 · Teva Branded Pharm

Proair Hfa

Albuterol Sulfate · Inhalation

Last checked: Nov 20, 2026Latest source record: Feb 25, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2004

Oct 29, 2004

Approved uses

3

Original approval plus efficacy supplements

Registered trials

793

238 Phase 3, 24 recruiting

FAERS reports

91,833

37,070 serious, 4,151 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

FEV 1 as Mean Percent Change from Test-Day Pre-Dose in a 6-Week Clinical Trial Day 1 Day 1 Image Day 43 Day 43 Image

What it is approved for

From the label in effect Jun 18, 2024.

Albuterol Sulfate HFA Inhalation Aerosol is a beta 2 -adrenergic agonist indicated for: Treatment or prevention of bronchospasm in patients 4 years of age and older with reversible obstructive airway disease. ( 1.1 ) Prevention of exercise-induced bronchospasm in patients 4 years of age and older. ( 1.2 ) 1.1 Bronchospasm Albuterol Sulfate HFA Inhalation Aerosol is indicated for the treatment or prevention of bronchospasm in patients 4 years of age and older with reversible obstructive airway disease. 1.2 Exercise-Induced Bronchospasm Albuterol Sulfate HFA Inhalation Aerosol is indicated for the prevention of exercise-induced bronchospasm in patients 4 years of age and older.

Mechanism: Albuterol sulfate is a beta 2 -adrenergic agonist. The pharmacologic effects of albuterol sulfate are attributable to activation of beta 2 -adrenergic receptors on airway smooth muscle. Activation of beta 2 -adrenergic receptors leads to the activation of adenylcyclase and to an increase in the intracellular concentration of cyclic-3', 5'-adenosine monophosphate (cyclic AMP). This increase of cyclic AMP is associated with the activation of protein kinase A, which in turn inhibits the phosphorylation of myosin and lowers intracellular ionic calcium concentrations, resulting in muscle...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • PROAIR HFA · ALBUTEROL SULFATE EQ 0.09MG BASE/INH · AEROSOL, METERED, INHALATION · Prescription · TE AB2

Clinical trials

Interventional ClinicalTrials.gov studies with "Albuterol" as an intervention, any sponsor and status, largest first.

All 793 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
FDA's data service returned an error (500). The numbers below may be missing or incomplete.

No FAERS reports name this application.

FAERS reports by year

By the date FDA received the report.

No reports.

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Proair HFA (Albuterol Sulfate)

2024 spending

$42K

Beneficiaries

428

549 claims

Per beneficiary

$98

$8.18 per unit

View as table
YearSpending
2020$190,243,881
2021$70,019,624
2022$35,724,521
2023$1,086,508
2024$42,089

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 985 on PubMed

Sponsor: Teva

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.